Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 1:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 132 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Quadrivalent Inactivated Influenza Vaccine Clear all
Completed No phase listed Observational Accepts healthy volunteers

Flucelvax (TIVc or QIVc) Pregnancy Registry

NCT03438487
View directory record Official record
Conditions
Influenza, Human, Pregnancy, Birth Defect
Interventions
Flucelvax Trivalent Influenza Vaccine, Flucelvax Quadrivalent Influenza Vaccine
Biological
Lead sponsor
Seqirus
Industry
Eligibility
Female only
Enrollment
692 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 4, 2022 · Synced Oct 7, 2026, 1:46 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Learn About Two or More Vaccines That Are Put Together as One Shot Against Infectious Lung Illnesses, Including COVID-19 and Respiratory Syncytial Virus (RSV).

NCT05886777
View directory record Official record
Conditions
Healthy Participants
Interventions
Combination [RSVpreF+BNTb162b2], Bivalent BNT162b2 (original/Omi BA.4/BA.5), RSVpreF, QIV, Normal Saline Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
65 Years and older
Enrollment
1,142 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
37
States / cities
Dublin, California • Huntington Beach, California • Lake Forest, California + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Oct 7, 2026, 1:46 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age

NCT06097273
View directory record Official record
Conditions
SARS-CoV-2, Influenza
Interventions
mRNA-1083, Placebo, Influenza Vaccine, COVID-19 Vaccine
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
50 Years and older
Enrollment
8,061 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
146
States / cities
Anniston, Alabama • Birmingham, Alabama • Cullman, Alabama + 122 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Oct 7, 2026, 1:46 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Senescent Immunity in Elders and Vaccine Responses (SILVER)

NCT04077424
View directory record Official record
Conditions
Flu Vaccine
Interventions
Fluzone-High Dose Quadrivalent, Fluad, Flublock
Biological
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
65 Years to 125 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 12, 2022 · Synced Oct 7, 2026, 1:46 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Fluarix/ FluLaval/ Fluarix Quadrivalent/ FluLaval Quadrivalent Vaccine Pregnancy Registry

NCT02148211
View directory record Official record
Conditions
Influenza
Interventions
Data collection
Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
Female only
Enrollment
507 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 12, 2020 · Synced Oct 7, 2026, 1:46 AM EDT
Recruiting No phase listed Observational

Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma

NCT03501576
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
Interventions
Inactivated Influenza Vaccine
Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 7, 2026, 1:46 AM EDT
Completed Not applicable Interventional

Seasonal Influenza Vaccine High Dose Boosting in Solid Organ Transplant Recipients

NCT05663463
View directory record Official record
Conditions
Solid Organ Transplant
Interventions
Fluzone High-Dose - 2 doses, Fluzone High-Dose - 1 dose of HD
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Oct 7, 2026, 1:46 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years

NCT06029933
View directory record Official record
Conditions
Influenza, Community-acquired Pneumonia, Cardiovascular Events
Interventions
Adjuvanted Quadrivalent Inactivated Influenza Vaccine (aIIV4), High-Dose Quadrivalent Inactivated Influenza Vaccine (HD-IIV4)
Biological
Lead sponsor
Kaiser Permanente
Other
Eligibility
65 Years and older
Enrollment
1,500,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 7, 2026, 1:46 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Two Doses of Multimeric-001 (M-001) Followed by Influenza Vaccine

NCT03058692
View directory record Official record
Conditions
Influenza, Influenza Immunisation
Interventions
Influenza Multimeric-001 Vaccine, Placebo, Quadrivalent Recombinant Seasonal Influenza Vaccine
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
3
States / cities
Iowa City, Iowa • Cincinnati, Ohio • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2020 · Synced Oct 7, 2026, 1:46 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older

NCT05624606
View directory record Official record
Conditions
Influenza Immunization
Interventions
Quadrivalent Influenza mRNA Vaccine MRT5410, Quadrivalent Recombinant Influenza vaccine RIV4, Quadrivalent Inactivated Influenza Standard Dose QIV-SD, Quadrivalent Inactivated Influenza High Dose QIV-HD
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
682 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
23
States / cities
Huntington Park, California • Long Beach, California • North Hollywood, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Oct 7, 2026, 1:46 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Response to Inactivated Influenza Vaccine in Lymph Tissue and Blood

NCT03898973
View directory record Official record
Conditions
Influenza
Interventions
Quadrivalent inactivated influenza vaccine (IIV)
Biological
Lead sponsor
Stanford University
Other
Eligibility
20 Years to 75 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 21, 2023 · Synced Oct 7, 2026, 1:46 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults

NCT03314662
View directory record Official record
Conditions
Influenza, Human
Interventions
MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV), Licensed MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-1), MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine Containing the Alternate B Strain (aTIV-2)
Biological
Lead sponsor
Seqirus
Industry
Eligibility
65 Years and older
Enrollment
1,778 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
20
States / cities
Mobile, Alabama • Anaheim, California • Redding, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2020 · Synced Oct 7, 2026, 1:46 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Effect of Tezepelumab on the Immune Response to Influenza Vaccination in Participants With Asthma

NCT05062759
View directory record Official record
Conditions
Moderate to Severe Asthma
Interventions
Tezepelumab, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 21 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
15
States / cities
Bakersfield, California • Huntington Beach, California • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 7, 2026, 1:46 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

The Safety, Tolerance, and Immunogenicity of MAS-1-Adjuvanted Seasonal Inactivated Influenza Vaccine (MER4101)

NCT02500680
View directory record Official record
Conditions
Influenza, Human
Interventions
MER4101, Inactivated Influenza Vaccine
Biological
Lead sponsor
Nova Immunotherapeutics Limited
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 6, 2019 · Synced Oct 7, 2026, 1:46 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Adjuvanted Seasonal Recombinant Quadrivalent Virus-Like Particles (QVLP) Influenza Vaccine in Adults 65 Years of Age and Older

NCT04622592
View directory record Official record
Conditions
Influenza
Interventions
Instramuscular vaccine
Biological
Lead sponsor
Medicago
Industry
Eligibility
65 Years and older
Enrollment
209 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
14
States / cities
Huntsville, Alabama • Chandler, Arizona • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2023 · Synced Oct 7, 2026, 1:46 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Resistance Exercise to Improve Flu Vaccine for Older Adults

NCT03736759
View directory record Official record
Conditions
Influenza, Human
Interventions
Exercise
Behavioral
Lead sponsor
University of Houston
Other
Eligibility
65 Years and older
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 17, 2022 · Synced Oct 7, 2026, 1:46 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in Adults Aged 18 Years and Above.

NCT02214225
View directory record Official record
Conditions
Influenza, Human
Interventions
Quadrivalent Influenza Vaccine (QIV), Trivalent Influenza Vaccine (TIV-1), Trivalent Influenza Vaccine (TIV-2)
Biological
Lead sponsor
Seqirus
Industry
Eligibility
18 Years and older
Enrollment
3,484 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
33
States / cities
Huntsville, Alabama • Los Angeles, California • San Diego, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Oct 7, 2026, 1:46 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines, 2016-2017 Formulations

NCT02908269
View directory record Official record
Conditions
Influenza
Interventions
Fluzone Quadrivalent vaccine, 2016-2017 formulation, No Preservative, Fluzone High-Dose, vaccine, 2016-2017 formulation
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
3 Years and older
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
2
States / cities
Bardstown, Kentucky • Metairie, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 29, 2022 · Synced Oct 7, 2026, 1:46 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study About Modified RNA Vaccines Against Influenza in Healthy Adults

NCT06436703
View directory record Official record
Conditions
Influenza, Human
Interventions
Influenza ModRNA Vaccine, Quadrivalent Influenza Vaccine (QIV)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,202 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
32
States / cities
Mobile, Alabama • Scottsdale, Arizona • Anaheim, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 7, 2026, 1:46 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) Compared to Fluzone® Quadrivalent in Children 6 to 35 Months of Age

NCT02242643
View directory record Official record
Conditions
Influenza
Interventions
FluLaval™ Quadrivalent, Fluzone® Quadrivalent
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Months to 35 Months
Enrollment
2,432 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
64
States / cities
Birmingham, Alabama • Dothan, Alabama • Tucson, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2018 · Synced Oct 7, 2026, 1:46 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

BPL-1357 Against H1N1 Influenza Virus Challenge

NCT07215858
View directory record Official record
Conditions
Influenza, Human
Interventions
BPL-1357 IM, BPL-1357 IN, Placebo IM, Placebo IN
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
129 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
2
States / cities
Bethesda, Maryland • Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 7, 2026, 1:46 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults

NCT05606965
View directory record Official record
Conditions
Influenza
Interventions
mRNA-1010, Egg-based Quadrivalent Influenza Vaccine, Adjuvanted Quadrivalent Influenza Vaccine, Inactivated Influenza Vaccine, mRNA-1345, mRNA-1045
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
172 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Oct 7, 2026, 1:46 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Three Influenza Vaccines in Children Aged 4 Years Old to Less Than 18 Years Old

NCT01992107
View directory record Official record
Conditions
Influenza
Interventions
QIVc, TIV1c, TIV2c
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
4 Years to 18 Years
Enrollment
2,333 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
88
States / cities
Huntsville, Alabama • Mobile, Alabama • Chandler, Arizona + 73 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2015 · Synced Oct 7, 2026, 1:46 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children

NCT02915302
View directory record Official record
Conditions
Influenza
Interventions
Fluzone Quadrivalent vaccine, No Preservative
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 35 Months
Enrollment
1,950 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
35
States / cities
Birmingham, Alabama • Harrisburg, Arkansas • Downey, California + 28 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2022 · Synced Oct 7, 2026, 1:46 AM EDT